Economic Aspects of Bladder Cancer: What Are the Benefits and Costs?

Overview

Journal World J Urol

Specialty Urology

Date 2009 Mar 10

PMID 19271220

Citations 180

Authors

K D Sievert

B Amend

U Nagele

D Schilling

J Bedke

M Horstmann

J Hennenlotter

S Kruck

A Stenzl

Affiliations

Soon will be listed here.

Abstract

Objective: Bladder cancer (BC) has the highest lifetime treatment costs per patient of all cancers. The high recurrence rate and ongoing invasive monitoring requirement are the key contributors to the economic and human toll of this disease. The purpose of this paper was to utilize the recent literature to identify opportunities for improving the benefits and costs of BC care.

Methods: A PubMed search was performed of recent publications concerning (BC) cost-effectiveness. We reviewed studies, reviews, opinion papers and cost-effectiveness analyses, focusing primarily on non-muscle-invasive bladder cancer (Ta/T1; NMIBC).

Results: New diagnostic tools such as urine markers may assist in more cost-effectively detecting BC at an earlier stage, however, these markers cannot replace the cystoscopy, which is the current standard of care. A photodynamic diagnostic tool (PDD) using hexylaminolevulinate (Hexvix) enhances tumor visibility and improves transurethral resection of bladder cancer (TURB) results, potentially reducing recurrence rates and lowering treatment costs. While the importance of BC research has been acknowledged, research investment has been continuously reduced during the last 5 years.

Conclusions: The economic burden of BC is well-characterized in the literature. This study suggests that new technologies (i.e., urine-based tests, PDD) and therapeutic regimes (intravesical chemotherapy, adjuvant immunotherapy) have significant potential to improve the diagnosis, treatment and on-going monitoring of BC patients, with potential improvements in clinical outcomes and concurrent cost-savings. A renewed interest and investment in BC research are required to ensure future advancements.

Citing Articles

Clinical utility of liquid biopsy in bladder cancer: The beginning of a new era.

Jia E, Agarwal G J Liq Biopsy. 2025; 6:100271.

PMID: 40027318 PMC: 11863694. DOI: 10.1016/j.jlb.2024.100271.

Nanostructured Formulations for a Local Treatment of Cancer: A Mini Review About Challenges and Possibilities.

Amparo T, Almeida T, Sousa L, Xavier V, Silva G, Brandao G Pharmaceutics. 2025; 17(2).

PMID: 40006574 PMC: 11859672. DOI: 10.3390/pharmaceutics17020205.

HOXA13 promotes immune evasion in bladder cancer by suppressing antigen processing and presentation, and phagosome pathways.

Chin F, Chan S, Chau D, Ong T, Abdul Razack A, Yusoff K Funct Integr Genomics. 2025; 25(1):44.

PMID: 39994130 DOI: 10.1007/s10142-025-01553-w.

Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer.

Smani S, DuBois J, Zhao K, Sutherland R, Rahman S, Humphrey P Curr Oncol Rep. 2025; .

PMID: 39976835 DOI: 10.1007/s11912-025-01645-7.

Prognostic role of prognostic nutritional index in patients with bladder cancer: a systematic review and meta-analysis.

Sun J, Li Z, Zhu X Front Oncol. 2025; 14:1486389.

PMID: 39917365 PMC: 11798790. DOI: 10.3389/fonc.2024.1486389.

References

DHallewin M, Bezdetnaya L, Guillemin F . Fluorescence detection of bladder cancer: a review. Eur Urol. 2002; 42(5):417-25. DOI: 10.1016/s0302-2838(02)00402-5. View

Bohle A, Jocham D, Bock P . Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2002; 169(1):90-5. DOI: 10.1016/S0022-5347(05)64043-8. View

Herr H . Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 1999; 163(1):60-1; discussion 61-2. View

Losa A, Hurle R, Lembo A . Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol. 1999; 163(1):68-71; discussion 71-2. View

Young M, Soloway M . Office evaluation and management of bladder neoplasms. Urol Clin North Am. 1999; 25(4):603-11. DOI: 10.1016/s0094-0143(05)70051-3. View

Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M . Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis. Urology. 2007; 69(2):275-9. DOI: 10.1016/j.urology.2006.10.017. View

Han , Schoenberg . The use of molecular diagnostics in bladder cancer. Urol Oncol. 2000; 5(3):87-92. DOI: 10.1016/s1078-1439(99)00052-6. View

Smith Jr J, Labasky R, COCKETT A, Fracchia J, Montie J, Rowland R . Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999; 162(5):1697-701. View

Sangar V, Ragavan N, Matanhelia S, Watson M, Blades R . The economic consequences of prostate and bladder cancer in the UK. BJU Int. 2005; 95(1):59-63. DOI: 10.1111/j.1464-410X.2005.05249.x. View

10.

Lotan Y, Svatek R, Sagalowsky A . Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer. 2006; 107(5):982-90. DOI: 10.1002/cncr.22084. View

11.

Konety B, Allareddy V . Influence of post-cystectomy complications on cost and subsequent outcome. J Urol. 2006; 177(1):280-7. DOI: 10.1016/j.juro.2006.08.074. View

12.

Yabroff K, Davis W, Lamont E, Fahey A, Topor M, Brown M . Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 99(1):14-23. DOI: 10.1093/jnci/djk001. View

13.

Cooksley C, Avritscher E, Grossman H, Sabichi A, Dinney C, Pettaway C . Clinical model of cost of bladder cancer in the elderly. Urology. 2008; 71(3):519-25. DOI: 10.1016/j.urology.2007.10.056. View

14.

Tolley D, Parmar M, Lallemand G, Benyon L, Fellows J, Freedman L . The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155(4):1233-8. View

15.

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

16.

Chapple C . Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: design and implementation. Eur Urol. 2001; 39 Suppl 3:31-6. DOI: 10.1159/000052565. View

17.

Daniltchenko D, Riedl C, Sachs M, Koenig F, Daha K, Pflueger H . Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005; 174(6):2129-33, discussion 2133. DOI: 10.1097/01.ju.0000181814.73466.14. View

18.

Konety B, Joyce G, Wise M . Bladder and upper tract urothelial cancer. J Urol. 2007; 177(5):1636-45. DOI: 10.1016/j.juro.2007.01.055. View

19.

Langa K, Fendrick A, Chernew M, Kabeto M, Paisley K, Hayman J . Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004; 7(2):186-94. DOI: 10.1111/j.1524-4733.2004.72334.x. View

20.

Kaasinen E, Rintala E, Hellstrom P, Viitanen J, Juusela H, Rajala P . Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol. 2002; 42(2):167-74. DOI: 10.1016/s0302-2838(02)00260-9. View